Moderna is trading 4.08% up at $195.10 on October 7, 2026, amid Tempus’s expanded collaboration with Moderna and Merck; available reporting does not establish that the announcement caused the gain.
- The multi-year collaboration supports potential commercialization of investigational cancer therapy intismeran autogene.
- Operational support includes sample collection and sequencing; the announcement disclosed no financial terms or approval.